27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The risk-benefit profile of anti-Aβ monoclonal antibodies (mAbs) in Alzheimer's disease (AD) remains unclear, especially concerning their safety and overall effects on AD progression and cognitive function. 4 key findings →
Design: meta-analysis Participants: 14,980 Evidence: high
Full summary, score breakdown and related studies → Original source
These results indicate a strong association between WMH and MCH, a common manifestation of cerebral amyloid angiopathy and ARIA-H. These results suggest that increased WMH volume may represent an early sign of vessel amyloidosis, likely prior to the emergence of MCH. 4 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
BackgroundDonanemab, a monoclonal antibody targeting amyloid-β (Aβ) plaques, has shown the ability to reduce cerebral amyloid burden in early Alzheimer's disease (AD). 2 key findings →
Design: systematic review Participants: 2,054 Evidence: high
Full summary, score breakdown and related studies → Original source
The prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes (change in ADAS-Cog score compared with control [n=354, 6·32, 95% CI 5·31-7·34]: 75 mg LMTM twice a day [n=257] -0·02, -1·60 to 1·56, p=0·9834, 125 mg LMTM twice a day [n=250] -0·43, -2·06 to 1·20, p=0·9323; change in ADCS-ADL score compared with control [-8·22, 95% CI -9·63 to -6·82]: 75 mg LMTM twice a day -0·93, -3·12 to 1·26, p=0·8659; 125 mg LMTM twice a day -0·34, -2·61 to 1·93, p=0·9479). 3 key findings →
Participants: 354 Evidence: high
Full summary, score breakdown and related studies → Original source
Newer GLDs were associated with a decreased risk of all-cause dementia in people with T2D. Because of the observational nature and significant heterogeneity between studies, the results should be interpreted with caution. 5 key findings →
Design: meta-analysis Participants: 819,511 Evidence: high
Full summary, score breakdown and related studies → Original source
We developed an endophenotype disease module-based methodology for Alzheimer's disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier. 2 key findings →
Design: case-control study Evidence: high
Full summary, score breakdown and related studies → Original source
Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life. 5 key findings →
Participants: 663 Evidence: high
Full summary, score breakdown and related studies → Original source
Behavioral treatment is a safe and effective conservative intervention that should be made more readily available to patients as a first-line treatment for urge and mixed incontinence. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A systematic approach to the management of pain significantly reduced agitation in residents of nursing homes with moderate to severe dementia. 4 key findings →
Design: randomized controlled trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source
This double-blind randomized trial does not support the hypothesis that the use of soy protein supplement containing isoflavones improves cognitive function, bone mineral density, or plasma lipids in healthy postmenopausal women when started at the age of 60 years or later. 2 key findings →
Design: randomized controlled trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source
Our systematic review indicates that a majority of studies examining the vision-cognition relationship report that VI is associated with more cognitive decline, cognitive impairment or dementia among older adults. 4 key findings →
Design: systematic review Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Patients with AD spectrum demonstrated altered GM abundance, which was differentially mediated by countries and clinical stages. 5 key findings →
Design: systematic review Participants: 427 Evidence: high
Full summary, score breakdown and related studies → Original source
Nineteen interventional studies, including 3,985 participants, were identified. 2 key findings →
Design: systematic review Participants: 3,985 Evidence: high
Full summary, score breakdown and related studies → Original source
EQ-5D utility scores averaged 0·03 (95% CI 0·01-0·05; p=0·0002) better with levodopa than with levodopa-sparing therapy; rates of dementia (hazard ratio [HR] 0·81, 95% CI 0·61-1·08, p=0·14), admissions to institutions (0·86, 0·63-1·18; p=0·4), and death (0·85, 0·69-1·06, p=0·17) were not significantly different, but the upper CIs precluded any substantial increase with levodopa compared with levodopa-sparing therapy. 179 (28%) of 632 patients allocated dopamine agonists and 104 (23%) of 460 patients allocated MAOBI discontinued allocated treatment because of side-effects compared with 11 (2%) of 528 patients allocated levodopa (p<0·0001). 2 key findings →
Design: randomized controlled trial Participants: 1,620 Evidence: high
Full summary, score breakdown and related studies → Original source
Contemporary healthcare policies are designed to shape the conditions that can help delay the institutionalization of patients with dementia. 4 key findings →
Design: systematic review Participants: 9,043 Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, less than half of patients diagnosed with schizophrenia have shown substantial clinical improvement after follow-up averaging nearly 6 years. 5 key findings →
Design: meta-analysis Participants: 51,800 Evidence: high
Full summary, score breakdown and related studies → Original source
Our findings indicate that high-speed resistance exercise training approaches are effective in improving cognitive function and physical performance in older adults with cognitive frailty. 3 key findings →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. 3 key findings →
Participants: 19,114 Evidence: low
Full summary, score breakdown and related studies → Original source
Participants with Elevated/High %p-tau217 exhibited accelerated cognitive decline, hippocampal atrophy, and significantly higher risks of progression to MCI (hazard ratio [HR] > 6.0) and dementia (HR > 9.9). 4 key findings →
Design: longitudinal study Participants: 1,204 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study investigated the potential association between levels of plasma neurofilament light chain (NfL) and cognitive function in patients suffering from Parkinson's disease (PD) in P.R. 3 key findings →
Design: meta-analysis Participants: 168 Evidence: high
Full summary, score breakdown and related studies → Original source
Plasma amyloid-β(Aβ)42/40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau181(p-tau181) are promising biomarkers for Alzheimer's disease (AD)-related pathology. 3 key findings →
Design: cohort study Participants: 1,270 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Seventy-four participants completed the study. 5 key findings →
Design: randomized controlled trial Participants: 84 Evidence: high
Full summary, score breakdown and related studies → Original source
Levels of apathy decreased slightly in both groups (mean decrease in AES-I of .61 points, 95% CI -3.54, 2.33 for TBI and .36 points, 95% CI -3.27, 2.55 for CAS). 5 key findings →
Design: randomized controlled trial Participants: 162 Evidence: high
Full summary, score breakdown and related studies → Original source
The present study will address several shortcomings of previous CCT studies. 5 key findings →
Design: randomized controlled trial Participants: 162 Evidence: high
Full summary, score breakdown and related studies → Original source
Narcolepsy type 1 is strongly associated with human leukocyte antigen (HLA)-DQB1*06:02; however, no significant associations between IH and HLA alleles have been reported. 4 key findings →
Design: meta-analysis Participants: 414 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →